IOL Chemicals' Q1 FY27 results are strong: Revenue up 37% to ₹756 Cr, EBITDA up 60.7% to ₹111 Cr (14.6% margin), PAT up 89.9% to ₹64.5 Cr.

Growth stems from high capacity use, better product mix & efficiency.

Non-ibuprofen APIs soared 67% YoY, now 43% of pharma revenue (target 50-55% by FY29). Exports hit 28.5%. Chemical business also strong.

FY27 guidance of 15-20% revenue growth, 14-15% EBITDA margin.

Management is confident in sustained growth through diversification, international expansion & operational efficiency. #IOLChemicals #Earnings